en · de · es · fr · pt
sr9009-notes.peptides6088.com › News › Background And Research Status — What the Evidence Shows

Background And Research Status — What the Evidence Shows

By Editorial Desk · published 2026-02-22 · last reviewed 2026-04-16 · News

Stenabolic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-04-16. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Related pages on this site

Reference notes

Activation of the PI3K–AKT signaling pathway by insulin-like growth factor 1 (IGF1) or by AKT2 overexpression led to the upregulation of CUX1 and was associated with resistance to apoptosis, whereas treatment of cells with the PI3K inhibitor LY294002 decreased CUX1 expression and increased apoptosis. Whether the discrepancies in the results and conclusions from these two studies can be explained by differences in cell-types or other reasons remains to be verified. The auxiliary role of CUX1 in base excision repair has raised the possibility that its tumor suppressor function may be linked to its function in DNA repair. CUX1 knockdown delays DNA repair in multiple cell lines. Mouse embryo fibroblasts (MEFs) derived from a Cux1-/- knockout mouse exhibit increased genomic instability23, moreover Cux1+/−- heterozygous MEFs are haploinsufficient for DNA repair18. Yet, whether CUX1 hemizygosity augments the risk of cancer by increasing the frequency of mutations and/or genomic rearrangements remains to be formally tested.

=== Apoptosis === One of the most studied roles of ceramide pertains to its function as a proapoptotic molecule. Apoptosis, or Type I programmed cell death, is essential for the maintenance of normal cellular homeostasis and is an important physiological response to many forms of cellular stress. Ceramide accumulation has been found following treatment of cells with a number of apoptotic agents, including ionizing radiation, UV light, TNF-alpha, and chemotherapeutic agents. This suggests a role for ceramide in the biological responses of all these agents. Because of its apoptosis-inducing effects in cancer cells, ceramide has been termed the "tumor suppressor lipid". Several studies have attempted to define further the specific role of ceramide in the events of cell death and some evidence suggests ceramide functions upstream of the mitochondria in inducing apoptosis. However, owing to the conflicting and variable nature of studies into the role of ceramide in apoptosis, the mechanism by which this lipid regulates apoptosis remains elusive.

=== Musical career === Pudzianowski often appears as a guest singer in the musical group Pudzian Band, formed by his brother Krystian. Their first single Zdobyć świat (To conquer the world), was released in 2006. In 2009, the group released an album, Dawaj na ring (Go, hit the ring).

Xanthoria parietina is a common and widespread lichen-forming fungus in the family Teloschistaceae. Commonly known as the yellow wall lichen, common orange lichen, or maritime sunburst lichen, this leafy lichen is known for its vibrant yellow to orange coloration and environmental adaptability. First described by Carl Linnaeus in 1753, it has become one of the most thoroughly studied lichens, contributing significantly to scientific understanding of lichen biology. Unlike many lichens that are sensitive to pollution, X. parietina grows in diverse habitats—including coastal rocks, urban walls, and tree bark—even in areas with high levels of air pollution and excess nitrogen. Its structure consists of small, overlapping lobes that typically measure less than 8 cm (3+1⁄8 in) across, with coloration that varies from bright orange in sun-exposed locations to greenish-yellow in shaded environments. The lichen represents a symbiotic partnership between a fungus and green algae of the genus Trebouxia. Its distinctive orange-yellow color comes from parietin, an anthraquinone pigment that accumulates in the outer cortex and serves as a natural sunscreen, protecting the algal partner from excessive light and ultraviolet radiation. Unlike many lichens that reproduce through specialized vegetative structures, X. parietina primarily relies on sexual reproduction through cup-shaped fruiting bodies (apothecia), each of which can release up to 50 spores per minute under humid conditions.

=== Generic names === Buserelin is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while buserelin acetate is its USANTooltip United States Adopted Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name, buséréline is its DCFTooltip Dénomination Commune Française, and buserelina is its DCITTooltip Denominazione Comune Italiana. While under development by Hoechst AG, buserelin was also known as HOE-766.

Sources: en.wikipedia.org

Notes from published material

The Mark V initially used a single power source for the flashlight, sprinting, and oxygen supply; in Half-Life 2: Episode Two the flashlight was given a separate power source to improve gameplay. The symbol on Gordon's HEV suit is the lowercase Greek letter Lambda, λ. This symbol is used by scientists to denote the decay constant of radioactive elements (related to the half-life of an element). As well as appearing on Gordon's suit, the symbol replaces the letter "a" in the game title (Hλlf-Life) and is the name of the complex in the Black Mesa Research Facility where teleportation experiments are conducted in the first game. The Lambda symbol is also seen in Half-Life 2 as a marking of the human resistance, seen close to hidden supplies and on the armbands of better equipped resistance fighters.

Relugolix is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR), with a half-maximal inhibitory concentration (IC50) of 0.12 nM. A dosage of relugolix of 40 mg once per day has been found to suppress estradiol levels to postmenopausal levels (<20 pg/mL) within 24 hours in premenopausal women. In the control group of women, estradiol levels fluctuated between 50 and 250 pg/mL. Estradiol levels have been found to return to normal concentrations within 4 weeks of discontinuation of relugolix in premenopausal women. The medication additionally suppresses levels of progesterone, luteinizing hormone, and follicle-stimulating hormone in premenopausal women. Relugolix at a dosage of 40 mg or more once per day has been found to reduce testosterone levels to sustained castrate levels (<20 ng/dL) in men. It additionally suppresses luteinizing hormone and follicle-stimulating hormone levels in men. Lower doses of relugolix (<40 mg/day) are under investigation for achieving partial sex hormone suppression in the treatment of endometriosis and uterine fibroids. This is intended to reduce the incidence and severity of menopausal symptoms such as hot flushes and decreased bone mineral density that are secondary to estrogen deficiency.

The decisive victory of Lieutenant-General Bernard Montgomery's Eighth Army over the Germans and Italians at the Second Battle of El Alamein in October–November 1942 turned the tide of the North African war strongly in favour of the Allies, and did much to revive Allied morale. The Rhodesians of the KRRC took part in the battle as part of the 7th Armoured Division under the XIII Corps, forming part of the initial thrust in the southern sector. The Rhodesian Anti-Tank Battery under Major Guy Savory also fought at El Alamein, supporting the Australian 9th Division as part of the XXX Corps. The fighting around "Thompson's Post" between 1 and 3 November was some of the fiercest Rhodesians took part in during the war. Hoping to knock out the Allied anti-tank guns before counter-attacking, the Germans concentrated intense artillery fire on the Australian and Rhodesian guns before advancing 12 Panzer IV tanks towards the weakest point of the Australian line. The Australian six-pounders had been largely disabled by the bombardment but most of the Rhodesian guns remained operational. The Rhodesian gunners disabled two Panzers and seriously damaged two more, compelling an Axis retreat, and held their position until being relieved on 3 November. One Rhodesian officer and seven other ranks were killed and more than double that number were wounded. For his actions at Thompson's Post, Sergeant J A Hotchin received the Distinguished Conduct Medal; Lieutenants R J Bawden and H R C Callon won the Military Cross and Trooper P Vorster the Military Medal.

== Career == Clausen was elected as a member of the Legislative Assembly for the Stanley constituency in the 2005 election. She was elected as a member of the Legislative Council, which was reconstituted into the Legislative Assembly with the implementation of the 2009 Constitution. Clausen was elected to the Legislative Council at the 2005 general election, but lost her seat four years later in the 2009 general election. In October 2019, Clausen became the Director of Natural Resources for the Falkland Islands Government. This role had a wide-ranging remit, from supporting the economic growth of the Islands to helping ensure the sustainability of fisheries, farming and natural environment. In 2024, it was announced that she had been appointed to succeed Andy Keeling as Chief Executive of the Falkland Islands Government. She is the first resident of the Falkland Islands and first woman to hold the position.

Sources: en.wikipedia.org

Background from the literature

On the second issue, CAS stated they could not "permit an athlete to establish how a substance came to be present in his body by little more a denial that he took it", that there was "nothing more than speculation, unsupported by any evidence of any kind", that Elsalam did not substantiate her hypothesis with any evidence aside from the receipt presented, that little attempt was made "to establish the causal link" and that it was "noteworthy" that Elsalam had not "produced a single piece of evidence demonstrating or even substantiating that other consumers (including athletes) having purchased and eating [sic] meat in Egypt within the relevant time have been subjected to food contamination with [ractopamine]" CAS upheld WADA's appeal, ruling a violation was committed, and that Elsalam had not met her burden of proof, so the violation "must be deemed to have been intentional". It was explicitly stated that they had "not pronounced the Athlete as a 'cheater'". Elsalam's ineligibility period was extended to four years. In October 2017 at a WADA conference, it was suggested in relation with ractopamine:

He also accused the Russian military of laying mines targeting his personnel as they retreated. The governor of Russia's Bryansk Oblast claimed that Ukrainian forces shelled a village along the international border, destroying a house. Two people were reportedly killed and two others injured when Ukrainian forces shelled a road in Maslova Pristan, Belgorod Oblast, while the Freedom of Russia Legion claimed responsibility for an attack on the village of Novaya Tavolzhanka and claimed that Russian government forces had killed two civilians after mistaking their vehicle for that of the legion. Long-range drones hit two towns in Smolensk Oblast, while an explosion was reported in a forest in Kaluga Oblast. Officials claimed that buildings were damaged in Bryansk and Kursk by Ukrainian shelling and a nighttime drone attack. Russian Deputy Prime Minister Viktoria Abramchenko said Russia sowed winter crops for the year's harvest in the territories it annexed during the invasion, providing state support worth 3 billion rubles ($37.1 million) to farmers in the occupied regions and harvesting grain, beans and rapeseed on 1.3 million hectares. The Chairman of the US Joint Chiefs of Staff General Mark Milley announced that Ukrainian soldiers had begun training in the use of M1 Abrams tanks pledged to Ukraine by the West. The United States approached Japan for supplies of TNT to be used in 155 mm caliber shells for Ukraine. According to Reuters, the Japanese government allowed the US government to purchase industrial TNT as it is not a military product.

Critical Reviews in Clinical Laboratory Sciences is a peer-reviewed medical journal that publishes review articles on all aspects of clinical laboratory sciences on an invitation-only basis. The journal is published by Taylor and Francis and the editor-in-chief is Khosrow Adeli (University of Toronto). According to the Journal Citation Reports, the journal has a 2019 impact factor of 4.677.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

Network